Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

Fiche publication

Date publication

juin 2024

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle , Dr DEBIEUVRE Didier

Tous les auteurs :
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38833966

Résumé

The RAS/MEK signaling pathway is essential in carcinogenesis and frequently altered in non-small-cell lung cancer (NSCLC), notably by KRAS mutations (KRASm) that affect 25%-30% of non-squamous NSCLC. This study aims to explore the impact of KRASm subtypes on disease phenotype and survival outcomes.